First Randomized controlled trial with ILP100 (INN emilommigene sigulactibact) published in The Lancet Discovery Sciences Journal eClinical Medicine
The first drug candidate on ILP100 is a topical formulation of ILP100 with ongoing programs in medical aesthetics in prediabetic, diabetic and obese patients undergoing surgery - and in diabetic foot ulcers
The second drug candidate on ILP100 is an Oral formulation being developed to treat immune checkpoint inhibitor induced colitis - affects 58% of patients
The third drug candidate is... well lets see - the potential is practically limitless! But we have received grant funding for investigating a new engineered bacteria in for lung indications.
Link to publication: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00191-8/fulltext